Comparing the risk of developing uveitis in patients initiating anti-tumor necrosis factor therapy for ankylosing spondylitis: an analysis of a large US claims database

References

• Elewaut D, Matucci-Cerinic M. Treatment of ankylosing spondylitis and extra-articular manifestations in everyday rheumatology practice. Rheumatology (Oxford) 2009;48:1029-35
   PubMed Web of Science ®Google Scholar
• Bremander A, Petersson IF, Bergman S, Englund M. Population-based estimates of common comorbidities and cardiovascular disease in ankylosing spondylitis. Arthritis Care Res 2011;63:550-6
   PubMed Web of Science ®Google Scholar
• Stolwijk C, van Tubergen A, Castillo-Ortiz JD, Boonen A. Prevalence of extra-articular manifestations in patients with ankylosing spondylitis: a systematic review and meta-analysis. Ann Rheum Dis 2013: published online 2 September 2013, doi: 10.1136/annrheumdis-2013-203582
   Google Scholar
• Rosenbaum JT, Smith JR. Anti-TNF therapy for eye involvement in spondyloarthropathy. Clin Exp Rheumatol 2002;20(6 Suppl 28):S143-5
   PubMed Web of Science ®Google Scholar
• Hamideh F, Prete PE. Ophthalmologic manifestations of rheumatic diseases. Semin Arthritis Rheum 2001;30:217-41
   PubMed Web of Science ®Google Scholar
• Zeboulon N, Dougados M, Gossec L. Prevalence and characteristics of uveitis in the spondyloarthropathies: a systematic literature review. Ann Rheum Dis 2008;67:955-9
   PubMed Web of Science ®Google Scholar
• Vander Cruyssen B, Ribbens C, Boonen A, et al. The epidemiology of ankylosing spondylitis and the commencement of anti-TNF therapy in daily rheumatology practice. Ann Rheum Dis 2007;66:1072-7
   PubMed Web of Science ®Google Scholar
• Braun J, Brandt J, Listing J, et al. Treatment of active ankylosing spondylitis with infliximab: a randomised controlled multicentre trial. Lancet 2002;359:1187-93
   PubMed Web of Science ®Google Scholar
• Pato E, Bañares A, Jover JA, et al. Undiagnosed spondyloarthropathy in patients presenting with anterior uveitis. J Rheumatol 2000;27:2198-202
   PubMed Web of Science ®Google Scholar
• Fernández-Melón J, Muñoz-Fernández S, Hidalgo V, et al. Uveitis as the initial clinical manifestation in patients with spondyloarthropathies. J Rheumatol 2004;31:524-7
   PubMed Web of Science ®Google Scholar
• Derhaag PJ, van der Horst AR, de Waal LP, Feltkamp TE. HLA-B27+ acute anterior uveitis and other antigens of the major histocompatibility complex. Invest Ophthalmol Vis Sci 1989;30:2160-4
   PubMed Web of Science ®Google Scholar
• Wendling D. Uveitis in seronegative arthritis. Curr Rheumatol Rep 2012;14:402-8
   PubMed Web of Science ®Google Scholar
• Schiffman RM, Jacobsen G, Whitcup SM. Visual functioning and general health status in patients with uveitis. Arch Ophthalmol 2001;119:841-9
   PubMed Web of Science ®Google Scholar
• Kirson NY, Rao S, Eldar-Lissai A, et al. Impact of extra-articular manifestations (EAMs) on medical resource utilization and cost of care for ankylosing spondylitis (AS) patients [abstract]. Ann Rheum Dis 2011;70(Suppl 3):428
   PubMedGoogle Scholar
• Hajj-Ali RA, Lowder C, Mandell BF. Uveitis in the internist’s office: are a patient’s eye symptoms serious? Cleve Clin J Med 2005;72:329-39
   PubMed Web of Science ®Google Scholar
• Santos Lacomba M, Marcos Martín C, Gallardo Galera JM, et al. Aqueous humor and serum tumor necrosis factor-α in clinical uveitis. Ophthalmic Res 2001;33:251-5
   PubMed Web of Science ®Google Scholar
• Braun J, Bollow M, Neure L, et al. Use of immunohistologic and in situ hybridization techniques in the examination of sacroiliac joint biopsy specimens from patients with ankylosing spondylitis. Arthritis Rheum 1995;38:499-505
   PubMed Web of Science ®Google Scholar
• Lindstedt EW, Baarsma GS, Kuijpers RW, van Hagen PM. Anti-TNF-alpha therapy for sight threatening uveitis. Br J Ophthalmol 2005;89:533-6
   PubMed Web of Science ®Google Scholar
• Levy-Clarke G, Jabs DA, Read RW, et al. Expert panel recommendations for the use of anti-tumor necrosis factor biologic agents in patients with ocular inflammatory disorders. Ophthalmology 2014;121:785-96
   PubMed Web of Science ®Google Scholar
• Braun J, Baraliakos X, Listing J, Sieper J. Decreased incidence of anterior uveitis in patients with ankylosing spondylitis treated with the anti-tumor necrosis factor agents infliximab and etanercept. Arthritis Rheum 2005;52:2447-51
   PubMed Web of Science ®Google Scholar
• Rudwaleit M, Rødevand E, Holck P, et al. Adalimumab effectively reduces the rate of anterior uveitis flares in patients with active ankylosing spondylitis: results of a prospective open-label study. Ann Rheum Dis 2009;68:696-701
   PubMed Web of Science ®Google Scholar
• Guignard S, Gossec L, Salliot C, et al. Efficacy of tumor necrosis factor blockers in reducing uveitis flares in patients with spondylarthropathy: a retrospective study. Ann Rheum Dis 2006;65:1631-4
   PubMed Web of Science ®Google Scholar
• Horst-Bruinsma IE, van Denderen JC, Visman I, et al. Decreased recurrence rate of anterior uveitis in ankylosing spondylitis treated with adalimumab: an interim analysis [abstract]. Arthritis Rheum 2010;62(Suppl 10):1933
   PubMedGoogle Scholar
• Lim LL, Fraunfelder FW, Rosenbaum JT. Do tumor necrosis factor inhibitors cause uveitis? A registry-based study. Arthritis Rheum 2007;56:3248-52
   PubMed Web of Science ®Google Scholar
• Wendling D, Paccou J, Berthelot J-M, et al. New onset of uveitis during anti-tumor necrosis factor treatment for rheumatic diseases. Semin Arthritis Rheum 2011;41:503-10
   PubMed Web of Science ®Google Scholar
• Sieper J, Koenig A, Baumgartner S, et al. Analysis of uveitis rates across all etanercept ankylosing spondylitis clinical trials. Ann Rheum Dis 2010;69:226-9
   PubMed Web of Science ®Google Scholar
• Fiorelli VM, Bhat P, Foster CS. Nonsteroidal anti-inflammatory therapy and recurrent acute anterior uveitis. Ocul Immunol Inflamm 2010;18:116-20
   PubMed Web of Science ®Google Scholar
• Dougados M, Berenbaum F, Maetzel A, Amor B. Prevention of acute anterior uveitis associated with spondyloarthropathy induced by salazosulfapyridine [in French]. Rev Rhum Ed Fr 1993;60:81-3
   PubMedGoogle Scholar
• Benitez-Del-Castillo JM, Garcia-Sanchez J, Iradier T, Bañares A. Sulfasalazine in the prevention of anterior uveitis associated with ankylosing spondylitis. Eye 2000;14:340-3
   PubMed Web of Science ®Google Scholar
• Muñoz-Fernández-Melón S, Hildago V, Fernández-Melón J, et al. Sulfasalazine reduces the number of flares of acute anterior uveitis over a one-year period. J Rheumatol 2003;30:1277-9
   PubMed Web of Science ®Google Scholar
• Berg IJ, Semb AG, van der Heijde D, et al. Uveitis is associated with hypertension and atherosclerosis in patients with ankylosing spondylitis: a cross-sectional study. Semin Arthritis Rheum 2014: published online 20 May 2014, doi: 10.1016/j.semarthrit.2014.05.017
   Google Scholar
• Bonafede M, Fox KM, Watson C, et al. Treatment patterns in the first year after initiating tumor necrosis factor blockers in real-world settings. Adv Ther 2012;29:664-74
   PubMed Web of Science ®Google Scholar
• Suhler EB, Smith JR, Wertheim MS, et al. A prospective trial of infliximab therapy for refractory uveitis: preliminary safety and efficacy outcomes. Arch Ophthalmol 2005;123:903-12
   PubMed Web of Science ®Google Scholar
• Diaz-Llopis M, García-Delpech S, Salom D, et al. Adalimumab therapy for refractory uveitis: a pilot study. J Ocul Pharmacol Ther 2008;24:351-61
   PubMed Web of Science ®Google Scholar
• Perez-Alvarez R, Pérez-de-Lis M, Ramos-Casals M; BIOGEAS study group. Biologics-induced autoimmune diseases. Curr Opin Rheumatol 2013;25:56-64
   PubMed Web of Science ®Google Scholar
• Wendling D, Prati C. Paradoxical effects of anti-TNF-α agents in inflammatory diseases. Expert Rev Clin Immunol 2014;10:159-69
   PubMed Web of Science ®Google Scholar